Search Results 571-580 of 18359 for alopecia

  1. Pediatric dermatology - Overview - Mayo Clinic

    Atopic dermatitis (eczema). Birthmarks, such as hemangioma and port-wine stain. Connective tissue disorders of the skin. Contact dermatitis. Dermatoses of ...

  2. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors - Mayo Clinic

    The patient must have recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior therapies except alopecia, neuropathy and other non ...

  3. A Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy in Patients with Gastric or Gastroesophageal Cancer - Mayo Clinic

    alopecia, neuropathy, and specific laboratory abnormalities). 29. Administration of a live vaccine within 28 days before first dose of study drug. 30 ...

  4. Ph 1b Study to Evaluate GSK2110183 in Combination with Bortezomib and Dexamethasone in Subjects with Multiple Myeloma - Mayo Clinic

    Unresolved toxicity (except alopecia) ≥ Grade 2 National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 [NCI ...

  5. Behcet disease - Symptoms and causes - Mayo Clinic

    Behcet (beh-CHET) disease, also called Behcet syndrome, is a rare condition. It causes blood vessel swelling, called inflammation, throughout the body. Behcet ...

  6. A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma - Mayo Clinic

    ... alopecia and decreased tendon reflex and to ≤ Grade 1 for all other effects at the time of enrollment, unless otherwise noted. Consult with the Lilly ...

  7. Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma - Mayo Clinic

    Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for ...

  8. A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma - Mayo Clinic

    Subject has not fully recovered from the acute toxicities (except alopecia) of any prior anti-cancer therapy. Subject requiring concomitant use of strong ...

  9. Testing The Addition Of An Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery To The Usual Surgery Alone For Treating Advanced Skin Cancer - Mayo Clinic

    ... alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. Physiologic ...

  10. A Study of IPI-926 for Patients with Myelofibrosis - Mayo Clinic

    ... alopecia; Females. Be of non-child bearing potential; If of child-bearing potential defined as a sexually mature woman who. Has not undergone surgical ...